Lu Yang

Lu Yang

Auto-generated profile, based on publicly available information

Lu Yang

Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, People’s Republic of China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2023 in JMIR Research Protocols
Verified
Journal Article
Open access
QCQianzi Che
Qianzi Che
TSTian Song
Tian Song
NLNing LIANG
Ning LIANG
JGJing Guo
Jing Guo
ZCZhao Chen
Zhao Chen
NSNannan Shi
Nannan Shi
Background: Although results from in vitro studies and small randomized controlled trials have shown positive effects of Dazhu hongjingtian injection (DZHJTI) on acute ischemic stroke (AIS), their generalizability to routine clinical practice remains to be established. Objective: The primary aim of this study is to evaluate the effectiveness of DZHJTI treatment for AIS with regard to changes in the stroke-related neurological deficit from baseline to outpatient follow-up, mortality, subsequent vascular events, disability, and traditional Chinese medicine syndrome in real-world clinical settings. By monitoring for adverse events or significant changes in vital signs and laboratory parameters, we also aim to assess the safety of DZHJTI. Methods: This prospective, multicenter cohort study plans to enroll 2000 patients with AIS within 14 days of symptom onset from 30 hospitals across China. Eligible patients will be followed up for 6 months after initiating medication treatments. The primary outcome will be the change in the National Institute of Health Stroke Scale score from baseline to outpatient follow-up. The secondary outcomes include overall mortality, stroke recurrence, new-onset major vascular events, global disability, and improvement of traditional Chinese medicine syndrome in 6 months. Adverse events or clinically significant changes in vital signs and laboratory parameters, regardless of the severity, will be recorded during the trial to assess the safety of DZHJTI. An augmented inverse propensity weighted estimator will be used to reduce variability and improve accuracy in average treatment effects estimation. Results: The clinical trial registration was approved in October 2022, and the recruitment and enrollment of participants started in November 2022. The study’s outcomes are expected to be published in 2025 in reputable, peer-reviewed health-related research journals. Conclusions: This real-world cohort study is the first to assess the effectiveness and safety of DZHJTI in treating AIS. It may provide additional clinical evidence, including the duration of response, long-term drug effectiveness, and subgroup efficacy data. The study results will be valuable for clinicians and patients seeking optimal treatment for AIS and could lead to better use of DZHJTI and improved patient outcomes. Trial Registration: ITMCTR ITMCTR2022000005; http://tinyurl.com/554ns8m5 International Registered Report Identifier (IRRID): DERR1-10.2196/52447

1 January 2025 in Human Mutation
Verified
Journal Article
Open access
LYLu Yang
Lu Yang
CBChunping Bo
Chunping Bo
MCMeiqi Chen
Meiqi Chen
BCBozhen Chen
Bozhen Chen
RZRui Zeng
Rui Zeng
XHXiaohong He
Xiaohong He
Objective: Ankylosing spondylitis (AS) is a long‐term inflammatory condition characterized by intricate pathogenesis and significant genetic predisposition. Current treatment methods cannot completely halt the progression of the disease. The purpose of this research is to discover possible therapeutic targets for AS by integrating Mendelian Randomization (MR), transcriptomics analysis, and machine learning, providing new options for the clinical treatment of AS.Methods: In this study, we initially pinpointed differentially expressed genes (DEGs) linked to AS from the GEO database and acquired cis‐eQTL data for these genes from the eQTLGen Consortium. Using MR and summary data–based Mendelian randomization (SMR) analyses, we screened for DEGs with causal relationships to AS. Subsequently, we analyzed the correlation between these causal genes and immune cell expression, constructed a risk prediction model, and identified key feature genes for AS. Next, we conducted phenome‐wide association studies (PheWASs) on the identified AS feature genes to predict their potential adverse effects as therapeutic targets. We obtained AS‐related therapeutic drugs from the DrugBank database and performed molecular docking analysis with AS feature genes. We used the CAIA collagen‐induced AS mouse model; we measured joint swelling and employed microCT, H&E, and Safranin O‐Fast Green staining to assess pathological changes in bone tissue. Additionally, we employed Western blot and RT‐qPCR to analyze the expression levels of genes associated with bone mineralization and AS feature genes in joint tissues.Results: A total of 1607 DEGs were obtained from the GEO database. After MR analysis and correction, 33 positive DEGs that have a causal relationship with AS were determined. Through the correlation analysis between these genes and the expressions of immune cells, it was found that 28 genes had significant regulatory relationships with 19 kinds of immune cells, with 55 pairs of negative regulatory relationships and 49 pairs of positive regulatory relationships, respectively. Four machine learning model algorithms determined the Top 5 genes (RIOK1, FUCA2, COL9A2, USP16, and TTC16) with the highest importance scores and constructed a nomogram to evaluate the risk probability. The results of the PheWAS showed that the five characteristic genes of AS had harmful or beneficial effects on numerous disease phenotypes of multiple types of diseases. Molecular docking indicated that 14 known AS treatment drugs had potential interactions with related genes. Using RT‐qPCR, we evaluated the expression levels of five key genes in the joint tissue of the CAIA collagen‐induced AS mouse model. Compared to the normal control group, we found that the levels of FUCA2 and USP16 were significantly elevated, while the levels of TTC16 were significantly reduced. In contrast, the expression of COL9A2 and RIOK1 mRNA showed no significant difference.Conclusion: Our research findings demonstrate that FUCA2, USP16, and TTC16 may serve as biomarkers for AS.

5 September 2023 in JMIR Preprints
Verified
Preprint
Open access
QCQianzi Che
Qianzi Che
TSTian Song
Tian Song
NLNing LIANG
Ning LIANG
JGJing Guo
Jing Guo
ZCZhao Chen
Zhao Chen
NSNannan Shi
Nannan Shi
BACKGROUND Although results from in vitro studies and small randomized controlled trials have shown positive effects of Dazhu hongjingtian injection (DZHJTI) on acute ischemic stroke (AIS), their generalizability to routine clinical practice remains to be established. OBJECTIVE The primary aim of this study is to evaluate the effectiveness of DZHJTI treatment for AIS with regard to changes in the stroke-related neurological deficit from baseline to outpatient follow-up, mortality, subsequent vascular events, disability, and traditional Chinese medicine syndrome in real-world clinical settings. By monitoring for adverse events or significant changes in vital signs and laboratory parameters, we also aim to assess the safety of DZHJTI. METHODS This prospective, multicenter cohort study plans to enroll 2000 patients with AIS within 14 days of symptom onset from 30 hospitals across China. Eligible patients will be followed up for 6 months after initiating medication treatments. The primary outcome will be the change in the National Institute of Health Stroke Scale score from baseline to outpatient follow-up. The secondary outcomes include overall mortality, stroke recurrence, new-onset major vascular events, global disability, and improvement of traditional Chinese medicine syndrome in 6 months. Adverse events or clinically significant changes in vital signs and laboratory parameters, regardless of the severity, will be recorded during the trial to assess the safety of DZHJTI. An augmented inverse propensity weighted estimator will be used to reduce variability and improve accuracy in average treatment effects estimation. RESULTS The clinical trial registration was approved in October 2022, and the recruitment and enrollment of participants started in November 2022. The study’s outcomes are expected to be published in 2025 in reputable, peer-reviewed health-related research journals. CONCLUSIONS This real-world cohort study is the first to assess the effectiveness and safety of DZHJTI in treating AIS. It may provide additional clinical evidence, including the duration of response, long-term drug effectiveness, and subgroup efficacy data. The study results will be valuable for clinicians and patients seeking optimal treatment for AIS and could lead to better use of DZHJTI and improved patient outcomes. CLINICALTRIAL ITMCTR ITMCTR2022000005; http://tinyurl.com/554ns8m5 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/52447

1 November 2025 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
LYLu Yang
Lu Yang
CCChitat Chang
Chitat Chang
WTWengFai Tam
WengFai Tam
YLYeqi Liang
Yeqi Liang
MCMeiqi Chen
Meiqi Chen
GQgong qiming
gong qiming
Objective: Ankylosing spondylitis (AS) is a chronic immune-mediated inflammatory disorder characterized by inflammation and pathological bone formation. Growing evidence suggests that mitochondrial dysfunction and cellular senescence are key drivers of disease progression. This study aimed to identify novel biomarkers linking these processes to AS. Methods: Transcriptomic datasets of AS patients and controls were analyzed to identify differentially expressed genes related to mitochondrial function and cellular senescence. Bioinformatics pipelines and multiple machine learning algorithms were used to screen candidate biomarkers, which were further validated in an independent dataset and in a collagen antibody-induced arthritis (CAIA) mouse model. Clinical diagnostic value was assessed using receiver operating characteristic analysis. Results: We identified 25 mitochondrial- and 8 senescence-related genes differentially expressed in AS. Consensus machine learning analysis highlighted COX17 and MATK as robust candidates with significant diagnostic performance. Immune infiltration analysis suggested strong correlations between these genes and altered immune cell subsets. In vivo validation confirmed upregulation of COX17 and downregulation of MATK in the AS mouse model, accompanied by enhanced osteogenic activity. Conclusion: COX17 and MATK are promising biomarkers linking mitochondrial dysfunction and cellular senescence to AS. Their diagnostic potential highlights new avenues for improving early disease detection and personalized therapeutic strategies.